Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870986 · ClinicalTrials.gov registry record · Phase 1
Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT01870986 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 210 participants.
The verdict
NCT01870986, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.
Interventions
- BIOLOGICAL PF-06410293
- BIOLOGICAL Humira (adalimumab-EU)
- BIOLOGICAL Humira (adalimumab-US)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870986
The ClinicalTrials.gov registry entry for NCT01870986 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06410293 is the first listed.
NCT01870986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870986 about?
NCT01870986 is a clinical study titled "Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)". This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 a...
What is the current status of trial NCT01870986?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2013-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01870986?
The interventions under investigation include: PF-06410293 (BIOLOGICAL), Humira (adalimumab-EU) (BIOLOGICAL), Humira (adalimumab-US) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01870986?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.